These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 19450096)

  • 1. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
    de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
    J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
    de Lissovoy G; Fraeman K; Teerlink JR; Mullahy J; Salon J; Sterz R; Durtschi A; Padley RJ
    Eur J Health Econ; 2010 Apr; 11(2):185-93. PubMed ID: 19582491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of levosimendan in patients with acute heart failure.
    Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
    J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.
    Lucioni C; D'Ambrosi A; Mazzi S; Pollesello P; Apajasalo M; Fedele F
    Adv Ther; 2012 Dec; 29(12):1037-50. PubMed ID: 23233357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
    Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
    Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
    Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
    JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
    J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine].
    Oliveira MT; Follador W; Martins ML; Canaviera R; Tsuji RL; Scipioni A; Barretto AC
    Arq Bras Cardiol; 2005 Jul; 85(1):9-14. PubMed ID: 16041448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case.
    Mardiguian S; Kivikko M; Heringlake M; Smare C; Bertranou E; Apajasalo M; Pollesello P
    J Med Econ; 2016; 19(5):506-14. PubMed ID: 26707159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials.
    Delaney A; Bradford C; McCaffrey J; Bagshaw SM; Lee R
    Int J Cardiol; 2010 Feb; 138(3):281-9. PubMed ID: 18817994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan compared with dobutamine in low output patients.
    Nieminen MS
    Minerva Anestesiol; 2003 Apr; 69(4):258-63. PubMed ID: 12766717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
    Duygu H; Ozerkan F; Zoghi M; Nalbantgil S; Yildiz A; Akilli A; Akin M; Nazli C; Ergene O
    Int J Clin Pract; 2008 Feb; 62(2):228-33. PubMed ID: 17949428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
    De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
    Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty.
    Samimi-Fard S; García-González MJ; Domínguez-Rodríguez A; Abreu-González P
    Int J Cardiol; 2008 Jul; 127(2):284-7. PubMed ID: 17643519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized clinical trials with levosimendan.
    Mebazaa A; Barraud D; Welschbillig S
    Am J Cardiol; 2005 Sep; 96(6A):74G-9G. PubMed ID: 16181826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.